Analysis of quinolone resistance mechanisms in Neisseria gonorrhoeae isolates in vitro

Gransden WR, Warren CA, Phillips I, Hodges M, Barlow D. Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet 1990;335:51.

Jephcott AE, Turner A. Ciprofloxacin resistance in gonococci. Lancet 1990;335:165.

Clendennen III TE, Hames CS, Kees ES, et al. In vitro antibiotic susceptibilities of Neisseria gonorrhoeae isolates in the Philippines. Antimicrob Agents Chemother 1992;36:277– 82.

Bogaerts J, Tello WM, Akingeneye J, et al. EVectiveness of norfloxacin and ofloxacin for treatment of gonorrhoea and decrease of in vitro susceptibility to quinolones over time in Rwanda. Genitourin Med 1993;69:196–200.

Knapp JS, Washington JA, Doyle LJ, et al. Persistence of Neisseria gonorrhoeae strains with decreased susceptibilities to ciprofloxacin and ofloxacin in Cleveland, Ohio, from 1992 through 1993. Antimicrob Agents Chemother 1994;38: 2194–6

Knapp JS, Ohye R, Neal SW, et al. Emerging in vitro resistance to quinolones in penicillinase-producing Neisseria gonorrhoeae strains in Hawaii. Antimicrob Agents Chemother 1994;38:2200–3.

Kam KM, Lo KK, Ho NgK, Cheung MM. Rapid decline in penicillinase producing Neisseria gonorrhoeae in Hong Kong associated with emerging 4-fluoroquinolone resistance. Genitourin Med 1995;71:141–4.

Tanaka M, Kumazawa J, Matsumoto T, Kobayashi I. High prevalence of Neisseria gonorrhoeae strains with reduced susceptibility to fluoroquinolones in Japan. Genitourin Med 1994;70:90–3.

Tanaka M, Matsumoto T, Kobayashi I, Uchino U, Kumazawa J. Emergence of in vitro resistance to fluoroquinolones in Neisseria gonorrhoeae isolated in Japan. Antimicrob Agent Chemother 1995;39:2367–70.

Belland RJ, Morrison SG, Ison C, Huang WM. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone resistant isolates. Mol Microbiol 1994;14:371–80.

Tanaka M, Otsuki M, Nishino T, et al. Mutation in DNA gyrA of norfloxacin-resistant clinical isolates of Neisseria gonorrhoeae. Genitourin Med 1996;72:295–7.

Tanaka M, Fukuda H, Hirai K, et al. Reduced uptake and accumulation of norfloxacin in resistant strains of Neisseria gonorrhoeae isolated in Japan. Genitourin Med 1994;70: 253–5.

Cohen SP, McMurry LM, Hooper DC, Wolfson JS, Levy SB. Cross-resistance to fluoroquinolones in multipleantibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane change in addition to OmpF reduction. Antimicrob Agents Chemother 1989;33: 1318–25.

Hirai K, Aoyama H, Irikura T, Iyobe S, Mitsuhasi S. DiVerence in susceptibility to quinolones outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother 1986;29:535–8.

Hooper DC, Wolfson JS, Bozza MA, Ng EY. Genetics and regulation of outer membrane protein by quinolone resistance loci nfxB, nfxC, and cfxB. Antimicrob Agents Chemother 1992;36:1151–4.

Kaatz GW, Seo SM, Ruble CA. EVux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993;37:1086–94.

Cohen SP, Hooper DC, Wolfson JS, et al. Endogenous active eZux of norfloxacin in susceptible Escherichia coli. Antimicrob Agents Chemother 1988;32:1187–91.

Toshida H, Nakamura M, Bogaki M, et al. Mechanism of action of quinolones against Escherichia coli DNA Gyrase. Antimicrob Agents Chemother 1993;37:839–45.

Messing J. New M13 vectors for cloning. Methods Enzymol 1983;101:20–78.

Sawai T, Hiruma R, Kawana N, et al. Outer membrane permeation of -lactam antibiotics in Escherichia coli, Proteus mirabilis, and Enterobacter cloacae. Antimicrob Agents Chemother 1982;22:585–92.

Hirai K, Aoyama H, Suzue S, et al. Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother 1986;30: 248–53.

Heisig P, Tschorny R. Characterization of fluoroquinoloneresistance of Escherichia coli selected in vitro. Antimicrob Agents Chemother 1994;38:1284–91.